The report discusses the potential market opportunity for Gilead Sciences' GS-5806 in the RSV space, estimating sales could top $2 billion. It highlights the high unmet need for RSV treatments, the promising phase 2a data for GS-5806, and the expected phase 2/3 trials. The report reiterates an 'Overweight' rating for Gilead Sciences, with a price target of $100.00, based on solid fundamentals in HIV, momentum in hepatitis C, and an emerging oncology pipeline.
documents/EFTA00300337.pdf
{}